Calistoga Pharmaceuticals is uniquely positioned to be the first company to demonstrate the clinical benefit of isoform-selective PI3 kinase inhibitors in patients with cancer and inflammatory diseases.
Calistoga Pharmaceuticals' CAL-101, an Oral Delta Isoform-Selective PI3 Kinase Inhibitor, Demonstrates Clinical Benefit in Patients with Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia…read more ›
Calistoga Pharmaceuticals Announces Two Oral Presentations on CAL-101 at 51st American Society of Hematology (ASH) Annual Meeting…read more ›
